Completed PHASE1 INTERVENTIONAL 5-arm NCT02313077

A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability and Immunogenicity of Heterologous Prime-Boost Regimens Using MVA-BN®-Filo and Ad26.ZEBOV Administered in Different Sequences and Schedules in Healthy Adults

Sponsor: Crucell Holland BV

Conditions Healthy

Interventions Ad26. ZEBOV MVA-BN-filo Placebo

Updated 6 times since 2017 Last updated: Apr 13, 2017 Started: Dec 17, 2014 Primary completion: Apr 17, 2015 Completion: Mar 15, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02313077, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Crucell Holland BV, it has been updated 6 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
May 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — May 2017 [monthly]

Completed PHASE1

First recorded

Dec 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Crucell Holland BV

Data source: Crucell Holland BV

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Oxford, United Kingdom